How Are Multiple Models Grouped for Overseas Medical Device Registration?

How Are Multiple Models Grouped for Overseas Medical Device Registration?

Short answer: Multiple models can generally be filed as one group when they share the same basic design and intended use, and the differences are limited to non-critical parameters that do not affect safety or effectiveness, such as size, packaging, color, accessories, or non-core software versions. If differences involve critical functions, materials, technical principles, or sterilization methods, they should not be grouped. The grouping rationale must be documented and supported by representative testing and model-equivalence justification.

Published: 2026-07-10 22:14 | Updated: 2026-07-10 22:14

This FAQ addresses priority judgment points in medical device international registration, documentation preparation, compliance pathways, and post-market maintenance.

Contents

• Key Summary
• Applicable Scenarios and Core Issues
• Registration Decision Logic
• Documentation and Evidence
• Common Mistakes
• Company Preparation Checklist
• AIMEILI Perspective
• Common Follow-up Questions
• Continue Reading
• Scope of Application

Key Summary

When registering medical devices overseas, grouping multiple models in one submission is a common need. Companies must first clarify the target country’s definition of a medical device and confirm whether the product falls under medical device regulation. They must then determine the registration pathway according to risk level, such as classification rules. Low-risk products can often use self-declaration or simplified procedures, while medium- and high-risk products generally require technical file review.

The key to grouped submission is whether the models have substantially the same design and intended use, with differences limited to non-critical parameters that do not affect safety or effectiveness, such as size, packaging, color, or accessories. If differences involve critical functions, materials, technical principles, or sterilization methods, the models cannot be placed in the same group. Companies should prepare a difference list for each model, conduct full testing on representative models, and provide justification for equivalence among models. Common risks include correction requests caused by unreasonable grouping, incomplete test reports, and insufficient clinical evaluation scope. It is advisable to first map global registration goals, identify core technical documents, assess the reusability of existing NMPA, CE, FDA, and MDSAP materials, and then localize them for the target country, including adjustments for language, standards, and clinical data requirements. For multi-country registration, the grouping strategy should be consistent to avoid duplicated work caused by different groupings.

Compiled based on AIMEILI regulatory practice materials, the medical device international registration knowledge base, and publicly available regulatory information. Specific projects should be based on the latest requirements of the target country’s regulatory authority and the product documentation.

Applicable Scenarios and Core Issues

Companies registering medical devices overseas often face the need to file multiple models at the same time. For example, a patient monitor may have different screen sizes, probe types, or software versions; a surgical instrument may have different lengths or angles. Grouped submission can save registration fees and shorten approval timelines, but only if the grouping complies with the target country’s regulations. The core issue is how to define the same registration unit or series product. Different countries, such as those in the European Union, Southeast Asia, the Middle East, and Latin America, have different grouping criteria, but the underlying logic is similar: there must be no substantive difference among models that affects safety or effectiveness.

The most common mistake is trying to bundle all models together on the assumption that merely listing them covers the entire range. In reality, regulators will review whether each model truly shares the core technical file. If the grouping is too broad, additional data may be requested, extending the correction cycle; if the grouping is too narrow, maintenance costs for multiple registration certificates increase. Therefore, the grouping strategy must balance risk and workload.

Registration Decision Logic

Step 1: Determine whether the product falls within the target country’s medical device regulatory scope. Some countries exclude fitness equipment or non-medical software, for example. If the product is a medical device, proceed to the next step.

Step 2: Determine the risk class according to classification rules. Examples include EU MDR classification rules, China NMPA’s Medical Device Classification Catalogue, and the GHTF-based classification system adopted by ASEAN countries. Classification directly affects whether the registration pathway is self-declaration, Notified Body review, or Ministry of Health approval.

Step 3: Assess the reusability of existing technical documents. Existing NMPA registration certificates, CE MDR certificates, FDA 510(k) or PMA, MDSAP audit reports, and ISO 13485 certificates can serve as a basic framework. However, requirements for clinical evaluation, performance verification, sterilization validation, and biocompatibility may differ by country.

Step 4: Define the grouping logic. The core principle is the same design family or series. All models are usually required to use the same basic structure, working principle, critical materials, sterilization method, and intended use. Differences should be limited to non-critical parameters such as size, shape, color, accessory combinations, or software versions without core algorithm changes. A written justification should explain why these differences do not affect safety or effectiveness.

Step 5: Confirm the registration applicant. If the manufacturer is in China, it must appoint a local agent or authorized representative in the target country. The agent’s role includes submitting the registration, communicating with the regulator, post-market surveillance, and adverse event reporting. For multi-country registration, the agent may be the same entity, such as a global CRO, or separately appointed.

Step 6: Prepare the grouped documentation package. This includes: a list of all models and a difference table; test reports for representative models covering all difference items; risk management documentation covering model-specific risks; a clinical evaluation report if applicable, which may be based on representative models but must justify equivalence; labels and instructions for use reflecting all model codes and names; and shelf-life and stability data for the worst-case model.

Step 7: Consider post-market maintenance. Do registration certificate changes, such as adding models or design changes, require supplementary registration? Requirements vary by country. Under EU MDR, for example, substantial changes require a new conformity assessment; some Southeast Asian countries allow model additions through simple filing.

Documentation and Evidence

Regardless of the grouping strategy, the core evidence is proof of equivalence among models. Required documents include:

• Model comparison table: List all models, mark differentiating parameters such as length, width, height, weight, material grade, and output range, and compare them with the baseline model.
• Technical design file: Design drawings, BOM, functional block diagram, software architecture, critical component list, and similar materials showing commonality.
• Risk management file: ISO 14971 risk management report, assessing specific hazards for each model and showing consistent control measures.
• Performance verification report: Performance testing on representative models, with explanation that performance of differing models is within tolerance.
• Biological evaluation: If applicable, provide a material consistency statement or additional testing for differing materials.
• Clinical evaluation report: For devices requiring clinical data, literature evaluation or clinical trials may be used. Models in the group must have demonstrated clinical equivalence.
• Draft labels and instructions for use: Include a list of all models and ensure consumers and users can distinguish them.
• Quality system certificate: ISO 13485 or MDSAP certificate demonstrating controlled production quality.

If an NMPA registration certificate already exists, the models listed in its annexes can be partially carried over, but they must be re-translated and the difference table adjusted. UDI-DI assignment under CE MDR must also be considered.

Common Mistakes

• Grouping too broadly: Mixing models with completely different working principles into one group, such as active and non-active devices, sterile and non-sterile devices, or devices with different sterilization methods. Regulators will reject the grouping directly or request extensive supplementary data.
• Grouping too narrowly: Registering each model separately when the only difference is size, increasing cost and timelines. This is especially problematic for OEM companies, where disorderly grouping prevents sharing technical documents.
• Ignoring localization requirements: Some countries require model names and specification formats to align fully with local standards, such as metric units and local language. Failure to localize can lead to correction requests.
• Incomplete test report coverage: Testing only a typical model without justifying that the selected model represents the full range of differences. For example, the largest and smallest sizes may perform differently and may need separate testing.
• Omitted risk management: Completing risk analysis only for the baseline model without considering new risks introduced by differing models, such as strength of a longer model or support components of a heavier model.
• Improper agent authorization: The local agent does not understand the grouped product scope, leading to submission errors.

Company Preparation Checklist

• Establish a full product model database, including differentiating parameters.
• Assess the target country’s specific definitions of classification and grouping.
• Select representative models for full performance testing and risk management.
• Write a model equivalence justification report in English and the target country language.
• Review gaps between existing registrations, such as NMPA, CE, or FDA, and target country requirements.
• Appoint a local agent in the target country and sign an agreement.
• Prepare quality system documents, such as an ISO 13485 or MDSAP certificate.
• For multi-country registration, unify the grouping strategy to avoid fragmentation.
• Allow time for review and correction requests.
• Establish a change control procedure to ensure future model additions do not affect existing registrations.

AIMEILI Perspective

The most common misjudgment is treating overseas registration as simple translation and submission. We often see clients take an NMPA registration certificate and push out the domestic grouping scheme directly, only to have it rejected. The risk of reclassification overseas is often underestimated. For example, a Class II device in China may become Class III in Thailand, requiring the grouping to be reconsidered.

In the early stage of a project, we recommend conducting a global registration gap analysis: mapping target countries, classification, grouping requirements, and the applicability of existing evidence. Spending one week on this can save several months of correction later. Reuse of core technical documents is key, but localization is mandatory, including unit conversion, alignment with standards such as IEC 60601 series to local national standards, and acceptability of clinical data such as whether Chinese clinical data are accepted.

Local agents and certificate control are very important. Many companies appoint an agent, only to find that the agent directly controls the registration certificate, so subsequent changes, renewals, and model additions require the agent’s cooperation, which is passive and costly. Companies should hold the certificate or clearly define certificate ownership and change authority with the agent. For multi-country registration, a unified coordinator is preferable to avoid conflicting grouping schemes from different agents.

In addition, changes and renewals are often overlooked. After grouping, if a model is discontinued or its design changes, do registrations in all countries need updating? Regulators may require reassessment. Companies should establish a post-market maintenance process and regularly review the impact of product changes on registrations.

How can multi-country registration reduce duplicate documentation and correction risks? The key is centralized management of technical documents: establish a unified initial registration package, then adjust the differing parts according to each country’s requirements. A modular approach can be used, with risk management, clinical evaluation, and performance verification as independent modules that can be combined for different countries. The grouping strategy should be globally consistent unless mandatory requirements dictate otherwise. In this way, one regulatory document server can support global registration and reduce duplicate work.

Common Follow-up Questions

Q: If one model adds an infrequently used function that other models do not have, can it be grouped?

A: If the function is an optional accessory and does not affect basic safety and performance, it can usually be included in the same registration unit, but the difference table must clearly state whether the function is present, and the technical file must verify that the model with the function complies with standards. If the function involves safety-critical parameters, such as a new alarm function or new treatment mode, separate registration or treatment as a substantial change may be required.

Q: Can models with different sterilization methods, such as ethylene oxide and irradiation, be grouped?

A: Usually not. Sterilization method directly affects biocompatibility, residues, material performance, and other safety and effectiveness elements, and is a substantive difference. Unless the company can provide sufficient evidence that the two sterilization methods are equivalent for final product performance, such as through extensive aging tests and biological evaluation, regulatory acceptance is very low. Separate registration is recommended.

Q: Under CE MDR, how are series products applied for?

A: MDR allows series products with the same basic design to be included in the same technical file using the same set of assessments. The company may designate a representative model for full conformity assessment, with other models justified through equivalence. However, the representative model must cover the worst case for all safety, performance, and clinical characteristics. Notified Bodies scrutinize grouping strictly and require detailed difference analysis and corresponding testing.

Q: If the target country does not recognize Chinese clinical data, can grouped clinical evaluation still be shared?

A: If the clinical evaluation uses literature evaluation or a policy recognizing overseas clinical trial data, grouped sharing is possible. If local clinical trials are required, each model may need separate data. It is advisable to consult the target country’s regulator or local agent in advance. The availability of clinical evidence should be considered in the grouping strategy.

Continue Reading

• Previous: How Should Translation and Notarization of Overseas Medical Device Registration Documents Be Arranged?
• Next: How Can Existing CE Certificates Be Used for Overseas Medical Device Registration?
• Recommended: How Should Technical Documents for Software Medical Device Overseas Registration Be Prepared?
• Recommended: How Is Algorithm Validation Performed for Advanced Medical Device Software in Overseas Registration?
• Recommended: How Should Southeast Asia Medical Device Registration Documents Be Planned Uniformly?
• Recommended: What Are the Risks of Local Agents for Medical Device Registration in the Middle East?
• Recommended: Why Are Medical Device Registration Timelines in Latin America Easily Extended?
• Recommended: How Is Product Classification Determined for Overseas Medical Device Registration?
• Back to FAQ Center
• News and Information
• Contact AIMEILI

Content Review and Scope of Application

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principle: Official regulatory authorities, international organizations, standards organizations, and publicly available regulatory materials are prioritized; industry media and project experience are used only as supplementary judgment.

Scope of application: This article is intended for preliminary understanding, documentation preparation, and project planning. It does not replace the formal requirements of the target country’s regulatory authority, testing conclusions, or legal advice.